Under the terms of the agreement, THB will manage Nexelis' biospecimen procurement activities, consolidating Nexelis' current sourcing channels with those of THB spanning over 20 countries worldwide.
With unrivaled expertise in immunology, and operating sites in North America (East and West Coast) and Europe, Nexelis is a provider of assay development and advanced laboratory testing services in the infectious diseases, metabolic diseases, and oncology fields.
Our versatile team of scientists, working with our advanced technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 100 new molecular entities, including blockbuster vaccines, anti-viral drugs, and immunotherapy, gene and cell therapy products.
Trans-Hit Biomarkers Inc is a worldwide biospecimen procurement CRO with the most extensive collection capability for biospecimens and clinical samples through an unrivalled worldwide partnered network of clinical partners and biobanks.
The company, led by a team with a solid background in biomedical research, advises and provides biopharma and diagnostic clients with the best solutions to help design, organize, and conduct sample collections in various fields including oncology, infectious and CNS diseases, among others.
THB manages the entire biospecimen acquisition process, from the initial sample request, to the moment the samples are delivered, and beyond. To learn more about THB, please, visit www.trans-hit.com.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886